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Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise 
from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other 
organs.1 T-cell acute lymphoblastic leukemia (T-ALL) is characterized by outgrowth of immature T-
cells.1 Gain-of-function mutations in NOTCH1 are common in T-ALL,2 making this receptor a 
promising target for drugs such as γ-secretase inhibitors (GSIs), which can block a proteolytic cleavage 
required for NOTCH1 activation.3 However, the enthusiasm for these therapies has been tempered by 
tumor resistance and paucity of information on the oncogenic programs regulated by oncogenic 
NOTCH1.3, 4 Therefore, the purpose of this study was to identify oncogenic NOTCH1-mediated 
molecular and genetic changes that contribute to T-ALL for future targeted therapies in order to improve 
leukemia treatment. 
The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL1, PRL2, 
and PRL3, represents an intriguing group of proteins that are currently being validated as potential 
biomarkers and therapeutic targets in human cancer, including breast cancer, ovarian cancer, and lung 
cancer.5 Notably, recent findings indicate that PRLs play important roles in the pathogenesis of 
hematological malignancies.6 For instance, PRL3 is highly expressed in BCR-ABL positive ALL, which 
may be responsible for the aggressive phenotype of the disease.7 PRL2 is located on human 
chromosome 1p35, a region often rearranged or amplified in malignant lymphoma and B-cell chronic 
lymphocytic leukemia (B-CLL).5 PRL2 mRNA is also highly expressed in primary human acute myeloid 
leukemia (AML) and T-ALL cells, suggesting that PRL2 may play an important role in the pathogenesis 
of T-ALL. 8, 9 We recently generated Prl2 deficient mice and found that PRL2 is required for extra-
embryonic development by negatively regulating PTEN, thereby activating the PI3K-Akt pathway.10 In 
a previous study, we observed that PRL2 enhances hematopoietic stem and progenitor cell (HSPC) 
proliferation through mediating SCF/KIT signaling. 11These findings suggest that PRLs may represent 
novel therapeutic targets for the treatment of hematological malignancies. 6-11 
 
  
To determine the functional requirement for PRL2 in the pathogenesis of T-ALL, we analyzed 
PRL2 expression in a gene expression profiling data set reported by Haferlach and colleagues.9 We 
found that PRL2 is highly expressed in both human B-ALL and T-ALL patient cells compared to 
normal control cells (Figure 1a). Given that PRL2 is important for the proliferation and survival of 
hematopoietic stem and progenitor cells,11 we determined the effect of genetic inhibition of PRL2 on 
human T-ALL cell proliferation by introducing shRNA targeting PRL2 into human T-ALL cells using 
lentiviruses. We found that knockdown of PRL2 decreased the proliferation and survival of human T-
ALL cells (Figures 1b and 1c; Supplementary Figures S1a and S1b). We also found that ectopic 
expression of a dominant-negative PRL2 mutant (PRL2-CSDA) decreased the proliferation of Molt4 
cells compared to mock transduced cells (Supplementary Figure S1c). 12 
In a previous study, we conducted an unbiased high-throughput small-molecule library screen 
and identified several compounds capable of inhibiting PRL activity.13 The lead compound (Cmpd-43) 
displayed a respectable pharmacokinetic profile in mouse with a plasma compound exposure Cmax=0.3 
mM and a half-life t1/2=15.8 h at a single 20 mg/kg intraperitoneal dosage. Intraperitoneally injection of 
15 mg/kg of PRLi daily for 3 weeks exhibited no toxicity and body weight and weights of major organs 
(liver, spleen, and kidney) were comparable to control mice. 13 We named the compound Cmpd-43 as 
PRL inhibitor (PRLi). To determine the effect of pharmacological inhibition of PRL2 on human T-ALL 
cells, we treated several human T-ALL cell lines with PRLi and measured cell viability. We found that 
pharmacological inhibition of PRL2 activity decreased proliferation and enhanced apoptosis in a 
dosage-dependent manner (Figures 1d and 1e). PRLi appears to be specific to leukemia cells and did not 
affect the viability of human cord blood mononuclear cells and HSPCs (Supplementary Figures S1d, 
S1e and S1f). Given that PRLi specifically blocks the PRL1-induced cell proliferation and migration 
through attenuation of both ERK1/2 and AKT activity,13 we treated two human T-ALL cell lines with 
PRLi and then measured the level of phosphorylated ERK using western blot analysis. We found that 
PRLi treatment resulted in decreased ERK phosphorylation in both Loucy and CEM cells (Figure 1f), 
  
suggesting that PRLi can inhibit ERK activation in leukemia cells. These results demonstrate that PRL2 
is important for the proliferation and survival of human T-ALL cells.  
More than 90% of human T-ALL show signs of constitutive NOTCH1 pathway activation and 
majority of human T-ALL lines are addicted to NOTCH1 function.4 Indeed, we found that PRL2 is a 
direct target of NOTCH1 signaling in mouse T cell progenitors (M.K. and Y.L. unpublished data). In 
order to test whether PRL2 is important for oncogenic NOTCH1 induced T-ALL in vivo, we transduced 
lineage- bone marrow progenitors from wild-type and Prl2 null mice with retrovirus encoding the 
constitutively active intracellular domain of NOTCH1 (NOTCH1-ICN1-EGFP). These cells were then 
transplanted into lethally irradiated recipient mice, and we monitored for the presence of CD4+CD8+ 
double positive (DP) leukemic cells in the peripheral blood.14 We found that the peripheral blood of 
control animals contained high number of donor-derived CD4+CD8+ DP cells at 5 and 7 weeks after 
transplantation, while only a minute number of leukemic cells were observed in recipient of Prl2 null 
cells (Figure 2a). The development of T-ALL in host that received wild-type cells transduced with 
NOTCH1-ICN1 retrovirus was rapid, with all control animals succumbing to the disease and died 9 
weeks following transplantation (Figure 2b). In contrast, animals repopulated with Prl2 null cells 
displayed significant protection from disease, with majority of animals remaining disease free 18 weeks 
following transplantation (Figure 2b). All control animals show enlarged spleen compared with recipient 
mice repopulated with PRL2 null cells (Figure 2c and Supplementary Figure S2a). Prl2-/- cells 
expressing NOTCH1-ICN1 showed long-term myeloid cell, B cell, CD4+, and CD8+ T cell engraftment 
in the surviving recipients (Supplementary Figure S2b). These results demonstrated that PRL2 is 
essential for the initiation and/or maintenance of T-ALL-induced by oncogenic NOTCH1. 
To determine whether PRL2 is essential for T-ALL maintenance, we introduced NOTCH1-ICN1 
into Prl2+/+ and Prl2-/- fetal liver cells using retroviruses and transplanted transduced cells (GFP+) into 
lethally irradiated recipient mice. All recipient mice repopulated with Prl2+/+ and Prl2-/- cells 
development leukemia with similar latency and penetrance (data not shown). Recently, the leukemia 
  
initiating cells (LICs) in a mouse model of T-ALL were characterized as c-Kit+ cells.15 We found that 
the frequency of leukemia-initiating cells (Kit+CD44+CD25+) in the spleen of leukemic mice are 
comparable between Prl2+/+ and Prl2-/-  groups (Figure 2d). We then transplanted 20,000 GFP+ cells 
purified from the spleen of primary recipients into secondary recipients and monitor leukemia 
development. Recipient mice repopulated with Prl2-/-  cells show delayed disease onset and extended 
survival compared to that of the Prl2+/+ cells (Figure 2e). To determine the role of PRL2 in leukemia-
initiating cell maintenance, we performed limiting dilution transplantation assays and transplanted 40 or 
200 leukemia-initiating cells (Kit+CD44+CD25+) purified from the spleen of primary recipients that 
have developed leukemia into lethally irradiated recipient mice. While most recipient mice repopulated 
with Prl2+/+ cells expressing NOTCH1-ICN1 developed leukemia and died within 40 days, none of the 
recipient mice repopulated with Prl2-/- cells developed leukemia (Figure 2f). Further, LICs were not 
detectable in the spleen of recipient mice repopulated with Prl2-/- LICs (Figure 2g). It appears that PRL2 
is important for the ability of LICs, defined immunophenotypically by flow cytometry, to recapitulate 
leukemia in secondary hosts rather than maintaining the number of LICs. Thus, these data demonstrate 
that PRL2 is important for the maintenance of T-ALL mediated by oncogenic NOTCH1. 
DELTA/ NOTCH1 association is one of the most important signals provided by the thymic 
environment to initiate T cell differentiation.16 Given that NOTCH1 signaling upregulates c-Kit 
expression in early T cell progenitors (ETPs) (M.K. and Y.L. unpublished data), we hypothesized that 
PRL2 may promote the pathogenesis of T-ALL through maintaining c-Kit+ LICs. To test this 
hypothesis, we introduced NOTCH1-ICN1 into Lin-Sca1+ BM cells isolated from Prl2+/+ and Prl2-/- 
mice and then cultured infected cells without stroma to examine cell differentiation and expansion. 
While Prl2+/+ Lin-Sca1+ cells expressing NOTCH1-ICN1 showed expansion, Prl2-/- Lin-Sca1+ cells 
failed to proliferate under this condition (Supplementary Figure S2c). We found the level of c-Kit 
proteins in Prl2+/+ cells expressing NOTCH1-ICN1 was significantly higher than that of the Prl2-/- cells 
both at day 11 and day 17 (Supplementary Figure S2d). Consistent with these observations, we observed 
  
high level of PRL2 mRNAs and proteins in the spleen of recipient mice transplanted with Lin- cells 
expressing NOTCH1-ICN1 (Supplementary Figures S2e and S2f). Further, treatment of some human T-
ALL cells with γ-secretase inhibitor (GSI) decreased the level of PRL2 proteins (Supplementary Figure 
S2g). Thus, our data suggest that oncogenic NOTCH1 may promote T-ALL development through 
sustaining PRL2 and c-Kit expression.  
To date, very little information exists in the literature on the role of PRL2 in human T-ALL.5,6 In 
this study, we have identified a critical role for PRL2 phosphatase in the proliferation and survival of 
human T-ALL cells. Further, we demonstrated that PRL2 is important for the leukemogenic potential of 
oncogenic NOTCH1 in vivo. Our findings suggest that pharmacological inhibition of PRL2 holds 
potential as a novel therapy for T cell acute lymphoblastic leukemia, and might also be applicable to the 
treatment of other human cancers.  
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FIGURE LEGENDS 
 
Figure 1. PRL2 is important for the proliferation and survival of human T-ALL cells. (a) PRL2 is highly 
expressed in both primary human B-ALL and T-ALL cells (Normal control cells were set to 1).8 (b) Tail-
7 cells were transduced with lentiviruses expressing control or PRL2 shRNA. The proliferation of 
transduced cells (GFP+) was measured over time (*p<0.05, n=3). (c) Tail-7 cells were transduced with 
lentiviruses expressing control or PRL2 shRNA were cultured with or without IL-7 for 2 days. The 
percentage of apoptotic cells was measured by Annexin V and PI staining (*p<0.05, n=3). (d) Inhibiting 
of PRL2 activity with a small molecule inhibitor (PRLi) decreases the viability of human T-ALL cell lines 
in a dosage-dependent manner. (e) Treatment of human T-ALL cell lines with PRL2 inhibitor (PRLi) 
induces apoptosis (***p<0.001, n = 3). (f) Immunoblot analysis of ERK phosphorylation in human T-
ALL cells following DMSO or a small molecule inhibitor (PRLi) treatment. Representative Western blot 
analysis of indicated proteins is shown. 
Figure 2. PRL2 promotes oncogenic NOTCH1 induced T-ALL in vivo. (a) Lethally irradiated B6.SJL 
mice were transplanted with Prl2+/+ or Prl2-/- progenitor cells expressing NOTCH1-ICN1, and peripheral 
blood was collected and the frequency of donor-derived (GFP+) CD4+CD8+ cells was determined by 
FACS analysis (n=10, ***p<0.001). (b) Lin- bone marrow cells isolated from Prl2+/+ and Prl2-/- mice 
were transduced with retroviruses expressing NOTCH1-ICN1 and equivalent number of transduced cells 
(GFP+) were injected into lethally irradiated recipient mice. Kaplan-Meier curve shows the survival of 
mice transplanted with cells expressing NOTCH1-ICN1 for the period of observation (n=12, 
***p<0.001). (c) Average spleen weight in recipient mice repopulated with Prl2+/+ or Prl2-/- cells 
expressing NOTCH1-ICN1 (n=10, **p<0.01). (d) Prl2+/+ and Prl2-/- fetal liver cells were transduced with 
retroviruses expressing NOTCH1-ICN1 and equivalent number of transduced cells (GFP+) were injected 
into lethally irradiated recipient mice. Representative flow cytometry blots showing the frequency of 
leukemia–initiating cells (Kit+CD44+CD25+) in the spleen of primary recipient mice 4 weeks following 
  
transplantation. (e) 20,000 GFP+ cells isolated from the spleens of primary recipient mice were injected 
into lethally irradiated recipient mice. Kaplan-Meier curve shows the survival of mice transplanted with 
cells expressing NOTCH1-ICN1 for the period of observation (***p<0.001, n=5). (f) 40 or 200 leukemia–
initiating cells (Kit+CD44+CD25+) purified from the spleens of primary recipient mice were injected into 
lethally irradiated recipient mice. Kaplan-Meier curve shows the survival of mice transplanted with cells 
expressing NOTCH1-ICN1 for the period of observation (****p<0.0001, n=5). (g) Representative flow 
cytometry blots showing the frequency of leukemia–initiating cells (Kit+CD44+CD25+) in the spleens of 
secondary recipient mice repopulated with leukemia–initiating cells (Kit+CD44+CD25+) expressing 
NOTCH1-ICN1. 
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Supplemental Methods 
Mice  
Wild type C57BL/6 (CD45.2+) and B6.SJL (CD45.1+) mice were purchased from the Jackson 
Laboratories. Prl2+/+ and Prl2-/- mice were maintained in the Indiana University Animal Facility and kept 
in Thorensten units with filtered germ-free air. All mice were 10-12 weeks of age at the time of analysis. 
Both male and female mice were utilized in the experiments. The Institutional Animal Care and Use 
Committee (IACUC) of the Indiana University School of Medicine approved all experimental procedures.  
Human T-ALL cell lines and cord blood cells 
Human T-ALL cell lines, including HPB-ALL, Loucy, CEM, Tail-7, Molt4, and Supt1, were obtained 
from ATCC. All cell lines were authenticated by SRT profiling and tested for mycoplasma 
contamination. Normal human cord blood samples were obtained after informed consent following the 
guidelines of the institutional review board of the Indiana University School of Medicine.  
Production of Lentivirus 
Lentiviral shRNA plasmid (pLB) was purchased from Addgene (11619). Oligonuculeotides targeting 
control (Luciferase) and human PRL2 mRNAs were cloned into the pLB plasmid. Oligonuculeotide 
sequences are available upon request. Lentiviral particles were generated by standard method using the 
third generation packaging system (pMDL, pMD2.G, and pRSV-Rev). Human T-ALL cell lines were 
infected with high-titer lentiviral suspensions. Twenty-four hours after infection, GFP-positive cells 
were sorted by FACS. The reduction of PRL2 proteins was determined by immunoblot analysis. 
Immunoblotting analysis 
Cells were washed with ice-cold PBS, and lysed on ice for 30 min in lysis buffer (50 mM Tris-HCl, pH 
  
7.4, 150 mM NaCl, 1% Triton X-100, and 10% glycerol) supplemented with a Complete Protease 
Inhibitor tablet (Roche Applied Science). Cell lysates were cleared by centrifugation at 15,000 rpm for 
10 min. The lysate protein concentration was estimated using a BCA protein assay kit (Pierce). The 
protein samples were boiled with sample buffer, separated by SDS-PAGE, transferred 
electrophoretically to a nitrocellulose membrane, and immunoblotted with appropriate antibodies, 
followed by incubation with horseradish peroxidase-conjugated secondary antibodies. The blots were 
developed by the enhanced chemiluminescence technique (ECL kit, GE Healthcare). Representative 
results from at least two independent experiments are shown. Antibodies were purchased from Cell 
Signaling (ERK, pERK, c-Kit, and Actin) and Abcam (Histone H3).  
Apoptosis assays 
Human T-ALL cell lines were treated with DMSO or different concentration of PRL inhibitor (PRLi). 
24 hours later, cell viability was evaluated by PI/Annexin V staining. Apoptotic cells were defined as PI-
Annexin V+. 
Production of Retrovirus 
Retroviral particles were produced by transfection of Phoenix E cells with the MSCV-IRES-GFP or 
MSCV- NOTCH1-ICN1-IRES-GFP plasmids, according to standard protocols.  Mouse hematopoietic 
progenitor cells were transduced on retronectin (Takara)-coated non-tissue culture plates with high-titer 
retroviral suspensions. Twenty-four hours after infection, GFP-positive cells were sorted by FACS. 
Transduced cells were then transplanted into lethally irradiated recipient mice. The presence of 
CD4+CD8+ double positive (DP) leukemic cells in the peripheral blood was measured by flow 
cytometry analysis. 
Real-time PCR 
  
For quantitative reverse-transcription polymerase chain reaction (RT-PCR), total RNA was isolated using 
the RNeasy Plus Micro Kit (QIAGEN), and then subjected to reverse transcription with random hexamers 
(SuperScript III kit; Invitrogen). Quantitative real-time PCR was performed with SYBR Green (Qiagen) 
on an ABI PRISM 7500 system. Gene specific primers were designed to flank introns so that products 
from cDNA could be distinguished from possible genomic DNA contamination. Primer sequences are 
available upon request. 
Statistical Analysis 
The animal sample size was based on previous studies evaluating the roles of oncogenic Notch in 
leukemia and POWER analysis. Using Chi-Square analysis, 5 mice per group will provide 80% 
POWER in detecting difference with 95% difference. Gehan-Breslow-Wilcoxon test was used for 
Kaplan-Meier survival curves. The other data were analyzed by paired or unpaired t test using GraphPad 
Prizm 5. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant. All experiments 
were repeated at least once. 
Supplementary Figure Legends 
 
Figure S1. (a) Tail-7 cells were transduced with lentiviruses expressing control (Sh-Luc) or PRL2 
shRNAs (Sh-PRL2-1 and Sh-PRL2-2). The level of PRL2 proteins was determined by western blot 
analysis. (b) CEM cells were transduced with lentiviruses expressing control or PRL2 shRNA. The 
proliferation of transduced cells (GFP+) was measured over time (*p<0.05, n=3). (c) Molt4 cells were 
transduced with retroviruses expressing dominant-negative PRL2 (PRL2-CSDA) or GFP. The 
proliferation of transduced cells (GFP+) was measured over time (**p<0.01, n=3). (d) PRL2 inhibitor 
(PRLi) treatment did not affect the viability of human cord blood mononuclear cells (p<0.1, n = 3). (e) 
The Frequency of CD34+ cells in human cord blood mononuclear cells was determined by flow cytometry 
analysis. Representative flow cytometry plots were shown. (f) PRL2 inhibitor (PRLi) treatment did not 
affect the viability of human cord blood CD34+ cells (p<0.1, n = 3). 
  
Figure S2. (a) Representative pictures for spleen isolated from recipient mice repopulated with Prl2+/+ 
or Prl2-/- cells expressing NOTCH1-ICN1. (b) Representative flow cytometry plots for analyzing myeloid 
cell, B cell, CD4+ and CD8+ T cell engraftment in the surviving recipients. (c) Lin-Sca1+ bone marrow 
cells isolated from Prl2+/+ and Prl2-/- mice were transduced with retroviruses expressing NOTCH1-ICN1 
or GFP. Transduced cells (GFP+) were cultured in liquid medium in the presence of SCF, FLT3 ligand, 
and IL-7. Cell proliferation was measured at day 11. (d) Lin-Sca1+ bone marrow cells isolated from Prl2+/+ 
and Prl2-/- mice were transduced with retroviruses expressing NOTCH1-ICN1 or GFP. Expression of c-
Kit in transduced cells (GFP+) was determined by western blot analysis at day11 and day17. Prl2-/- cells 
(GFP+) failed to growth at day17. (e) The level of PRL2 mRNA in spleenocytes isolated from recipient 
mice repopulated with Prl2+/+ cells expressing NOTCH1-ICN1 was determined by quantitative real-time 
PCR analysis (*p<0.05, n=3). (f) The level of PRL2 proteins in spleenocytes isolated from recipient mice 
repopulated with Prl2+/+ and Prl2-/- cells expressing NOTCH1-ICN1 was determined by western blot 
analysis. Splenocytes from Prl2+/+ mice or recipients repopulated with Prl2+/+ bone marrow cells were 
used as controls. (g) γ-secretase inhibitor (GSI) treatment decreased the level of PRL2 proteins in some 
human T-ALL cell lines. 
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